<DOC>
	<DOCNO>NCT02632123</DOCNO>
	<brief_summary>Idiopathic pulmonary fibrosis ( IPF ) progress scar disease lung average survival 30-36 month since time diagnosis . The clinical course IPF highly variable , patient remain stable prolonged period time , even absence medical treatment , others experience rapid relentless progression . In case , clinical course consist stepwise rather steady decline , period stability alternate acute respiratory worsening . The variability clinical course make challenge define prognosis patient , importantly , determine right time window lung transplantation ( LTx ) referral , list priority status wait list . The risk stratification score ( RISE ) new stag system IPF base MRC dyspnea score , physiology variable ( pulmonary function test ) capture Composite Physiologic Index ( CPI ) , 6-minute walk distance . RISE show predict survival newly diagnose patient IPF good individual clinical , functional radiographic variable . RISE also predict survival wait list patient assess list LTx .</brief_summary>
	<brief_title>Validation Risk Stratification Score Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>The objective study validate RISE reliable tool predict survival patient newly diagnose IPF prospectively follow period 3 year , death lung transplant . This observational , prospective cohort study . Inclusion criterion new diagnosis IPF base American Thoracic Society/European Respiratory Society criterion ( Am J Respir Crit Care Med 2011 ; 183:788-824 ) . A pattern consistent IPF confirm expert radiologist , unless surgical lung biopsy available . Patients newly diagnose IPF include study . At visit , typically every 4 month , MRC dyspnea score ( MRCDS ) , pulmonary function test ( FEV1 , FVC DLCO ) , 6-minute walk distance ( 6MWD ) record . The RISE calculate ad described Eur Respir J 2012 ; 40:101-109 . MRCDS , PFTs 6MWD part standard care IPF routinely obtain visit IPF patient ILD clinic ( typically every 4 month ) . Patients prospectively follow period 3 year mortality event record . Mortality primary endpoint . Acute exacerbation ( AEs ) IPF , define AJR Am J Roentgenol 1997 ; 168:79-83 , also record . AEs secondary endpoint . At end study period , baseline RISE longitudinal change RISE test predictor mortality . Other individual variable wil also test predictor mortality include age time diagnosis , time onset symptom diagnosis ( month ) , gender , body mass index , smoke history ( pack-years ) , PFTs , 6MWD ( meter % predict ) , radiographic fibrosis score high resolution chest CT scan ( HRCT ) time diagnosis . Values express meanÂ±SD . Comparisons survivor non-survivors make unpaired t-test Mann-Whitney U-test , appropriate . The optimal cut-off value different variable detect mortality AE assess use receiver operate characteristic ( ROC ) analysis . Survival evaluate use Kaplan-Meier curve log-rank test . Cox proportional hazard regression analysis use identify significant variable predict survival status . Results summarize hazard ratio , represent relative risk die result specific characteristic observation period . Variables select via univariate analysis ( p &lt; 0.05 ) evaluate multivariate Cox regression analysis . p-values &lt; 0.05 regarded significant .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>A new diagnosis IPF base American Thoracic Society/European Respiratory Society criterion ( Am J Respir Crit Care Med 2011 ; 183:788824 ) confirm panel expert chest radiologist . Interstitial lung disease IPF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>idiopathic pulmonary fibrosis</keyword>
	<keyword>outcome</keyword>
	<keyword>prognosis</keyword>
	<keyword>survival</keyword>
</DOC>